Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

NEW YORK, Jan. 19, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

http://www.reportlinker.com/p0761765/Antipsychotics-Market-to-2017---Patent-Expiries-for-Zyprexa-Abilify-Seroquel-and-Geodon-and-the-Launch-of-Generic-Versions-Will-Limit-Commercial-Opportunities-for-Pipeline-Molecules.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules", which provides insights into the global antipsychotics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the antipsychotics market for bipolar disorder and schizophrenia. The report also provides the share of generics in the global antipsychotics market as well as in each indication market. The report examines the global bipolar disorder and schizophrenia treatment usage patterns. In addition, geographical distribution of the antipsychotics market across the US, the top five countries of Europe and in Japan is provided. The report also includes insights into the antipsychotics R&D product pipeline and explores the competitive landscape including the major players in the antipsychotics market. Finally, the report includes an analysis of the Mergers and Acquisitions (M&A) and licensing agreements that have recently taken place in the antipsychotics market.

GBI Research analysis shows that antipsychotics remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder and generated $14,080m of revenue in 2010 in the top seven geographies including the US, the UK, Spain, Italy, France, Germany and Japan. Newer agents (atypical antipsychotics) such as AstraZeneca's Seroquel, Eli Lilly's Zyprexa, Bristol-Myers Squibb's Abilify, J&J's Risperdal and Pfizer's Geodon continued to dominate the global antipsychotics market and achieved blockbuster status due to their better efficacy. Schizophrenia represents 70% while bipolar disorder contributed 30% to the global antispychotics market. The patent expiries of leading antispychotics followed by the immediate entry of generic versions are expected to increase the price competition in the antipsychotic market. The market is expected to decline at a CAGR of 0.4% from $14,080m in 2010 to $13,733m in 2017.

Scope

- Data and analysis on the antipsychotics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the antipsychotics market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Share of the generics in the global antipsychotics market and for the market of each indication that is covered in the report.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global antipsychotic market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb and Johnson & Johnson.

- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the antipsychotics market.

Reasons to buy

- Align their product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Antipsychotics Market to 2017 - Introduction 7

2.1 GBI Report Guidance 7

3 Antipsychotics Market to 2017 - Global Market Overview 8

3.1 Introduction 8

3.2 Revenue Forecasts 9

3.2.1 Generic Share 10

3.3 Annual Cost of Treatment 11

3.4 Top Antipsychotics Drug Products 12

3.4.1 Seroquel (quetiapine) 13

3.4.2 Zyprexa (olanzapine) 13

3.4.3 Abilify (aripiprazole) 14

3.4.4 Risperdal (risperidone) 14

3.4.5 Geodon (ziprasidone) 14

3.5 Newer Antipsychotics 15

3.5.1 Fanapt (iloperidone) 15

3.5.2 Saphris / Sycrest (asenapine) 16

3.5.3 Invega Sustenna (paliperidone palmitate extended release injectable suspension) 16

3.5.4 Latuda (lurasidone Hcl) 17

4 Antipsychotics Market to 2017 - Geographical Landscape 18

4.1 Revenue Analysis by Geography 18

4.2 The US 19

4.2.1 Revenue 19

4.2.2 Annual Cost of Treatment 20

4.3 Top Five Countries of Europe 21

4.3.1 Revenue 21

4.3.2 Annual Cost of Treatment 23

4.4 Japan - Antipsychotics Market 24

4.4.1 Revenue 24

4.4.2 Annual Cost of Treatment 25

5 Antipsychotics Market to 2017 - Therapeutic Landscape 26

5.1 Bipolar Disorder - Antipsychotics Market 26

5.1.1 Introduction 26

5.1.2 Revenue 28

5.1.3 Annual Cost of Treatment 31

5.1.4 Treatment Usage Patterns 32

5.2 Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder 34

5.2.1 Drivers for Bipolar Disorder Therapeutics Market 34

5.2.2 Barriers for Bipolar Disorder Therapeutics Market 34

5.3 Schizophrenia - Antipsychotics Market 35

5.3.1 Introduction 35

5.3.2 Revenue 37

5.3.3 Annual Cost of Treatment 40

5.3.4 Treatment Usage Patterns 41

5.4 Drivers and Barriers to the Antipsychotics Market for Schizophrenia 43

5.4.1 Drivers for the Schizophrenia Therapeutics Market 43

5.4.2 Barriers for the Schizophrenia Therapeutics Market 43

6 Antipsychotics Market to 2017 - Product Pipeline Analysis 44

6.1 Introduction 44

6.1.1 Antipsychotics Market to 2017- Discovery Stage Molecules 46

6.1.2 Antipsychotics Market to 2017- Pre-clinical Stage Molecules 47

6.1.3 Antipsychotics Market to 2017- Phase I Stage Molecules 48

6.1.4 Antipsychotics Market to 2017- Phase II Stage Molecules 50

6.1.5 Antipsychotics Market to 2017- Phase III Stage Molecules 52

6.1.6 Antipsychotics Market to 2017- NDA Filed Molecules 52

6.1.7 NDA filed molecules 52

7 Antipsychotics Market to 2017 - Competitive Landscape 54

7.1 Market Share Analysis 54

7.1.1 AstraZeneca 55

7.1.2 Eli Lilly 56

7.1.3 Bristol-Myers Squibb (BMS) 57

7.1.4 Johnson & Johnson (J&J) 58

7.1.5 Pfizer 59

8 Antipsychotics Market to 2017 - M&A Landscape 60

8.1 M&A Deals (2007-2011) 61

8.1.1 M&A Deals by Region 61

8.1.2 M&A Deals by Value 62

8.1.3 M&A Deals by Year 63

8.1.4 Summary of M&A Deals (2009-2011) 65

8.2 Licensing Deals 67

8.2.1 Licensing Deals by Region 70

8.2.2 Licensing Deals by Year 71

8.2.3 Deal Summary (2010-2011) 72

8.3 Co-development Deals 74

8.3.1 Co-development Deals by Region 76

8.3.2 Co-development Deals by Year 77

8.3.3 Deal Summary (2010 - 2011) 78

9 Antipsychotics Market to 2017 - Appendix 80

9.1 Market Definitions 80

9.2 Abbreviations 80

9.3 Research Methodology 81

9.3.1 Coverage 81

9.3.2 Secondary Research 81

9.3.3 Primary Research 82

9.3.4 Therapeutic Landscape 82

9.3.5 Geographical Landscape 86

9.3.6 Pipeline Analysis 86

9.3.7 Competitive Landscape 86

9.3.8 Expert Panel Validation 86

9.4 Contact Us 86

9.5 Disclaimer 86

9.6 Sources 87

1.1 List of Tables

Table 1: Antipsychotics Market, Global, Revenue, ($m), 2002-2010 9

Table 2: Antipsychotics Market, Global, Revenue Forecast, ($m), 2010-2017 9

Table 3: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2002-2010 11

Table 4: Antipsychotics Market, Global, Annual Cost of Treatment ($), 2010-2017 11

Table 5: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 12

Table 6: Antipsychotics Market, Newer Antipsychotics, 2009-2010 15

Table 7: Antipsychotics Market, The US, Revenue ($m), 2002-2010 19

Table 8: Antipsychotics Market, The US, Revenue Forecast ($m), 2010-2017 19

Table 9: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2010 20

Table 10: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2010-2017 20

Table 11: Antipsychotics Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 21

Table 12: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 22

Table 13: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 23

Table 14: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 23

Table 15: Antipsychotics Market, Japan, Revenue ($m), 2002-2010 24

Table 16: Antipsychotics Market, Japan, Revenue Forecast ($m), 2010-2017 24

Table 17: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2010 25

Table 18: Antipsychotics Market, Japan, Annual Cost of Treatment, ($), 2010-2017 25

Table 19: Antipsychotics Market, Bipolar Disorder, Global, Revenue ($m), 2002-2010 28

Table 20: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2010-2017 28

Table 21: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2010 29

Table 22: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2010-2017 30

Table 23: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 31

Table 24: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 31

Table 25: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2010 32

Table 26: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2010-2017 33

Table 27: Antipsychotics Market, Schizophrenia, Global, Revenue ($m), 2002-2010 37

Table 28: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2010-2017 37

Table 29: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2010 38

Table 30: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2010-2017 39

Table 31: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 40

Table 32: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 40

Table 33: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2010 41

Table 34: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2010-2017 42

Table 35: Antipsychotics Market, Discovery Stage Molecules, 2011 46

Table 36: Antipsychotics Market, Preclinical Stage Molecules, 2011 47

Table 37: Antipsychotics Market, Phase I Stage Molecules, 2011 48

Table 38: Antipsychotics Market, Phase II Stage Molecules, 2011 50

Table 39: Antipsychotics Market, Phase III Stage Molecules, 2011 52

Table 40: Antipsychotics Market, NDA Filed Molecules, 2011 52

Table 41: Antipsychotics Market, Global, M&A Deals, 2007-2011 64

Table 42: Antipsychotics Market, Global, Licensing Deals, 2007-2011 67

Table 43: Antipsychotics Market, Global, Co-developments Deals, 2008-2011 74

1.2 List of Figures

Figure 1: Antipsychotics Market, Global, Revenue Forecast, ($m), 2002-2017 9

Figure 2: Antipsychotics Market, Global, Generic Share, (%), 2010 and 2017 10

Figure 3: Antipsychotics Market, Global Annual Cost of Treatment ($), 2002-2017 11

Figure 4: Antipsychotics Market, Revenue of Leading Antipsychotics,($m),2008-2010 12

Figure 5: Antipsychotics Market, Revenue Analysis by Geography, (%), 2010 18

Figure 6: Antipsychotics Market, The US, Revenue Forecast, ($m), 2002-2017 19

Figure 7: Antipsychotics Market, The US, Annual Cost of Treatment ($), 2002-2017 20

Figure 8: Antipsychotics Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 21

Figure 9: Antipsychotics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 23

Figure 10: Antipsychotics Market, Japan, Revenue Forecast ($m), 2002-2017 24

Figure 11: Antipsychotics Market, Japan, Annual Cost of Treatment ($), 2002-2017 25

Figure 12: Antipsychotics Market, Bipolar Disorder, Treatment Algorithm, 2011 27

Figure 13: Antipsychotics Market, Bipolar Disorder, Global, Revenue Forecast ($m), 2002-2017 28

Figure 14: Antipsychotics Market, Bipolar Disorder, Revenue by Country, ($m), 2002-2017 29

Figure 15: Antipsychotics Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 31

Figure 16: Antipsychotics Market, Bipolar Disorder, Global, Treatment Usage Patterns (Thousand), 2002-2017 32

Figure 17: Antipsychotics Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 34

Figure 18: Antipsychotics Market, Schizophrenia, Treatment Algorithm, 2011 36

Figure 19: Antipsychotics Market, Schizophrenia, Global, Revenue Forecast ($m), 2002-2017 37

Figure 20: Antipsychotics Market, Schizophrenia, Global, Revenue by Country, ($m), 2002-2017 38

Figure 21: Antipsychotics Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2017 40

Figure 22: Antipsychotics Market, Schizophrenia, Global, Treatment Usage Patterns (Thousand), 2002-2017 41

Figure 23: Antipsychotics Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 43

Figure 24: Antipsychotics Market, Product Pipeline Molecules by Clinical Stages of Development, (%), 2011 44

Figure 25: Antipsychotics Market, Product Pipeline Molecules by Indication, (%), 2011 45

Figure 26: Antipsychotics Market, Global Market Share Analysis,(%),2011 54

Figure 27: Antipsychotics Market, SWOT Analysis of AstraZeneca, 2010 55

Figure 28: Antipsychotics Market, SWOT Analysis of Eli Lilly, 2010 56

Figure 29: Antipsychotics Market, SWOT Analysis of Bristol-Myers Squibb, 2010 57

Figure 30: Antipsychotics Market, SWOT Analysis of Johnson & Johnson, 2010 58

Figure 31: Antipsychotics Market, SWOT Analysis of Pfizer, 2010 59

Figure 32: Antipsychotics Market, Global, Strategic Consolidation, 2007-2011 60

Figure 33: Antipsychotics Market, Global, M&A Deals by Region, 2007-2011 61

Figure 34: Antipsychotics Market, Global, M&A Deals by Value ($m), 2007-2011 62

Figure 35: Antipsychotics Market, Global, M&A Deals by Year, 2007-2011 63

Figure 36: Antipsychotics Market, Global, Licensing Deals by Region, 2007-2011 70

Figure 37: Antipsychotics Market, Global, Licensing Deals by Year, 2007-2011 71

Figure 38: Antipsychotics Market, Global Co-development Deals by Region, 2008-2011 76

Figure 39: Antipsychotics Market, Global, Co-development Deals by Year, 2008-2011 77

Figure 40: GBI Research Market Forecasting Model 85

Companies mentioned

AstraZeneca

Eli Lilly

Bristol-Myers Squibb (BMS)

Johnson & Johnson (J&J)

Pfizer

To order this report:

Pathology Industry: Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker